Imidazoline receptors, subclassification, and drug-induced regulation.
Overall, as summarized in TABLE 6, a variety of responses to chronic drug treatment were observed depending on the drug, the tissue, and the ligand. Taken together these studies support the concept that the three ligands bind to distinct sites. In addition, they suggest that idazoxan and possibly yohimbine act as agonists at the I2 site in kidney. Finally, the lack of regulation of the I1 site in hindbrain is consistent with the low incidence of withdrawal symptoms reported with imidazoline-preferring drugs.
Hamilton
C A
CA
Department of Medicine and Therapeutics, University of Glasgow, Western Infirmary, Scotland.
D000818:Animals; D006801:Humans; D007093:Imidazoles / Q000378:metabolism*; D054755:Imidazoline Receptors; D007668:Kidney / Q000378:metabolism; D011955:Receptors, Drug / Q000145:classification* / Q000187:drug effects / Q000378:metabolism; D012249:Rhombencephalon / Q000378:metabolism
D007093:Imidazoles; D054755:Imidazoline Receptors; D011955:Receptors, Drug